{"nctId":"NCT01895972","briefTitle":"Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT","startDateStruct":{"date":"2013-07-05","type":"ACTUAL"},"conditions":["Glaucoma","Ocular Hypertension"],"count":130,"armGroups":[{"label":"Latanoprostene Bunod","type":"EXPERIMENTAL","interventionNames":["Drug: Latanoprostene bunod"]}],"interventions":[{"name":"Latanoprostene bunod","otherNames":["BOL-303259-X"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects must have a diagnosis of open angle glaucoma (OAG) (including normal-tension glaucoma \\[NTG\\],pigmentary or pseudoexfoliative glaucoma), or ocular hypertension (OHT) in one or both eyes.\n* Subjects must meet the following IOP requirements at Visit 3 (Eligibility, Day 0\\[after washout for the subjects already on treatment\\]): mean/median IOP ≥15 mmHg and ≤36 mmHg at 10 AM in at least 1 eye; and IOP ≤36 mmHg in both eyes.\n* Subjects with a corrected Decimal visual acuity (VA) or a Best-Corrected Decimal Visual Acuity (BCVA) of 0.5 or better in both eyes.\n\nExclusion Criteria:\n\n* Subjects who are unable to discontinue contact lens use during and for 15 minutes following instillation of study drug and during study visits.\n* Subjects who are unable to discontinue other eye drop medications such as artificial tears for 15 minutes prior to and 15 minutes after instillation of study drug.\n* Subjects with a central corneal thickness greater than 600 μm in either eye.\n* Subjects with any condition that prevents reliable applanation tonometry in either eye.\n* Subjects with advanced glaucoma with a mean deviation (MD) \\< -12 dB, a history of split fixation, or a field loss threatening fixation in either eye.\n* Subjects with any condition that prevents clear visualization of the fundus.\n* Subjects who are monocular (fellow eye is absent).\n* Subjects with aphakia in either eye.\n* Subjects with an active corneal disease in either eye.\n* Subjects with severe dry eye in either eye.\n* Subjects with a history/diagnosis of a clinically significant or progressive retinal disease in either eye.\n* Subjects with very narrow angles and subjects with angle closure congenital, or secondary glaucoma, and subjects with history of angle closure in either eye.\n* Subjects with any intraocular infection or inflammation in either eye within 3 months prior to Visit 1 (Screening).\n* Subjects with a history of ocular laser surgery in either eye within the 3 months (90 days) prior to Visit 1 (Screening).\n* Subjects with a history of incisional ocular surgery or severe trauma in either eye within 3 months prior to Visit 1 (Screening).","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Intraocular Pressure","description":"Change from baseline in intraocular pressure (IOP) following treatment with latanoprostene bunod 0.024% (instilled QD in the evening) with IOP assessed every 4 weeks from Week 4 to Week 52.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.30","spread":"2.746"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.57","spread":"2.610"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.76","spread":"2.846"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.79","spread":"2.742"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.94","spread":"2.707"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.94","spread":"2.877"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.93","spread":"2.703"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.04","spread":"2.789"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.32","spread":"2.778"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.25","spread":"2.629"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.12","spread":"2.862"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.12","spread":"2.741"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.25","spread":"2.633"}]}]}]},{"type":"PRIMARY","title":"Clinical Safety","description":"Ocular adverse events reported over one year of once daily dosing of latanoprostene bunod 0.024%. Below is the percentage of subjects with \\>/=1 ocular AE Specifics of AEs are captured in the AE section.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":130},"commonTop":["Conjunctival hyperemia","Growth of eyelashes","Eye irritation","Eye pain","Iris hyperpigmentation"]}}}